What is Zacks Research’s Estimate for BDRX FY2026 Earnings?

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) – Investment analysts at Zacks Research issued their FY2026 EPS estimates for shares of Biodexa Pharmaceuticals in a note issued to investors on Monday, March 30th. Zacks Research analyst D. Bautz anticipates that the company will earn $0.00 per share for the year. The consensus estimate for Biodexa Pharmaceuticals’ current full-year earnings is ($1.25) per share. Zacks Research also issued estimates for Biodexa Pharmaceuticals’ FY2027 earnings at $0.00 EPS.

Several other analysts also recently issued reports on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen downgraded Biodexa Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

Biodexa Pharmaceuticals Stock Up 1.0%

Biodexa Pharmaceuticals stock opened at $0.62 on Wednesday. Biodexa Pharmaceuticals has a 12 month low of $0.60 and a 12 month high of $19.30. The stock’s 50 day moving average is $1.18 and its 200-day moving average is $3.81.

Biodexa Pharmaceuticals shares are going to reverse split before the market opens on Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 3rd.

Biodexa Pharmaceuticals (NASDAQ:BDRX) last issued its quarterly earnings data on Friday, March 27th. The company reported $0.70 earnings per share (EPS) for the quarter.

Institutional Trading of Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Armistice Capital LLC bought a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned about 14.71% of Biodexa Pharmaceuticals as of its most recent SEC filing. Institutional investors own 17.51% of the company’s stock.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.